Almirall (LBTSF) Stock Price, News & Analysis

Company Overview

Almirall is a research-driven pharmaceutical company headquartered in Barcelona, Spain. Founded in 1943, the firm has evolved into a specialist in dermatology, dedicating its efforts to understanding and treating a range of inflammatory and chronic skin conditions. Over the decades, Almirall has built a reputation for its targeted R&D approach and its commitment to improving patient outcomes in dermatological care.

The company’s core activities span the research, development, manufacturing and marketing of prescription therapies for skin diseases. Its marketed portfolio includes products such as Actikerall, a topical treatment for actinic keratosis; Solaraze, a diclofenac-based gel for actinic keratosis and superficial basal cell carcinoma; and Skilarence (apremilast), an oral therapy for plaque psoriasis. Almirall’s pipeline features investigational small molecules and biologics aimed at conditions like eczema, hidradenitis suppurativa and other inflammatory dermatoses.

Almirall operates across Europe, North America and Latin America, leveraging a network of subsidiaries, local partnerships and strategic alliances to distribute its products. The company maintains research centres in Barcelona and other European locations, collaborating with academic institutions and biotech firms to accelerate innovation. Looking ahead, Almirall continues to pursue growth in its core dermatology franchise while exploring adjacent opportunities through licensing deals and co-development agreements.

Key Stats

• Today's Range: $15.35 to $15.35
• 50-Day Range: $15.35 to $15.35
• 52-Week Range: $13.36 to $15.47
• Volume: N/A
• Average Volume: 200 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Almirall Stock Analysis - MarketRank™

Almirall scored higher than 1% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

Almirall has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Almirall has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Almirall is -205.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Almirall is -205.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Almirall has a short interest ratio ("days to cover") of 999.99, which indicates bearish sentiment.

Change versus previous month

Short interest in Almirall has recently increased by 38.34%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Almirall does not currently pay a dividend.

Dividend Growth

Almirall does not have a long track record of dividend growth.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Almirall insiders have not sold or bought any company stock.

Percentage Held by Institutions

16.10% of the stock of Almirall is held by institutions.

Company Calendar

• Today: 7/02/2026
• Next Earnings (Estimated): 7/24/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:LBTSF
• CIK: N/A
• Web: www.almirall.com
• Phone: 34 93 291 30 00
• Fax: N/A
• Employees: 1,996
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A